Your browser doesn't support javascript.
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
2.
Transpl Immunol ; 69: 101445, 2021 12.
Artículo en Inglés | MEDLINE | ID: covidwho-1347842

RESUMEN

The coronavirus disease 2019 (COVID-19) has swept the world, posing a serious threat to people's lives and health. Several cases of COVID-19 infection in renal transplant recipients (RTRs) have been reported, but the treatment and prognosis have not been fully elucidated. We followed-up with RTRs infected with SARS-CoV2 in our center and classified them as five clinical types-asymptomatic, mild, moderate, severe, and critical. The immunosuppressive agents were not adjusted in asymptomatic carriers and mild patients, the former was mainly treated by isolation, and the latter was treated by low-dose intravenous immunoglobulin (IVIG) to enhance immunity. For moderate or severe patients, the immunosuppressive agents were largely reduced or even interrupted, low-dose IVIG was adopted, and low-dose methylprednisolone (MP) was used to inhibit inflammation and rejection. Immunosuppressants were discontinued early in critical patients; IVIG, high-dose MP, and antibiotics were used. Meanwhile, all patients received at least one antiviral drugs. After aggressive treatment, three patients developed acute kidney injury, and two showed reversal, while the remaining one lost the allograft kidney; one patient died, while other patients were discharged. For different clinical types of RTRs infected with COVID-19, personalized therapies were essential, Meanwhile, patients with COVID-19 infection may have different outcomes due to their different clinical manifestations.


Asunto(s)
Tratamiento Farmacológico de COVID-19 , Huésped Inmunocomprometido/inmunología , Inmunosupresores/uso terapéutico , Trasplante de Riñón , SARS-CoV-2/efectos de los fármacos , Lesión Renal Aguda/patología , Adulto , Antivirales/uso terapéutico , COVID-19/inmunología , COVID-19/patología , COVID-19/terapia , Femenino , Humanos , Inmunización Pasiva/métodos , Inmunoglobulinas Intravenosas/uso terapéutico , Inmunosupresores/efectos adversos , Masculino , Metilprednisolona/uso terapéutico , Persona de Mediana Edad , Pronóstico , Receptores de Trasplantes , Sueroterapia para COVID-19
3.
Transpl Immunol ; 67: 101395, 2021 08.
Artículo en Inglés | MEDLINE | ID: covidwho-1199110

RESUMEN

Since its emergence in December 2019 many end-stage renal disease (ESRD) patients have been infected with coronavirus disease 2019 (COVID-19). Herein, we describe the case of an ESRD patient who received a kidney transplant after recovering from COVID-19. We described the clinical course of COVID-19 and kidney transplant management, including the patient's symptoms, laboratory results, computed tomography, and antibody profiles. He recovered well, without complications. Chest computed tomography, PCR, and IgG results indicated no recurrence of COVID-19 during the subsequent two weeks. Therefore, kidney transplantation is feasible in an ESRD patient who has recovered from COVID-19, under a normal immunosuppressive regimen.


Asunto(s)
COVID-19/terapia , Huésped Inmunocomprometido , Fallo Renal Crónico/cirugía , Trasplante de Riñón , Receptores de Trasplantes , Adulto , Antivirales/uso terapéutico , Glomerulonefritis/cirugía , Humanos , Inmunosupresores/efectos adversos , Inmunosupresores/uso terapéutico , Masculino , SARS-CoV-2
4.
Cardiorenal Med ; 10(6): 470-475, 2020.
Artículo en Inglés | MEDLINE | ID: covidwho-809051

RESUMEN

With the global spread of SARS-Cov-2 infections, increasing numbers of COVID-19 cases have been reported in transplant recipients. However, reports are lacking concerning the treatment and prognosis of COVID-19 pneumonia in renal transplant recipients with acute cardiorenal syndrome. We report here the complete clinical course of a renal transplant recipient with critical COVID-19 pneumonia. In the early phase of SARS-Cov-2 infection, the patient exhibited extensive lung lesions and significant acute kidney and heart injuries, which required treatment in the ICU. After correcting the arrhythmia and heart failure, the patient recovered quickly from the acute kidney injury with a treatment of intensive diuresis and strict control of fluid intake. Without cessation of oral immunosuppressive agents, the patient presented a delayed and low antibody response against SARS-Cov-2 and reappeared positive for the virus twice after being discharged. Nevertheless, the patient's pneumonia continued to improve and he fully recovered in 69 days. This effectively treated case may be meaningful and referable for the treatment of COVID-19 pneumonia in other transplant recipients with acute cardiorenal syndrome.


Asunto(s)
COVID-19/complicaciones , Síndrome Cardiorrenal/etiología , Trasplante de Riñón/efectos adversos , SARS-CoV-2/genética , Enfermedad Aguda , Formación de Anticuerpos/inmunología , COVID-19/diagnóstico , COVID-19/epidemiología , COVID-19/virología , Síndrome Cardiorrenal/tratamiento farmacológico , Diuréticos/uso terapéutico , Humanos , Huésped Inmunocomprometido/inmunología , Inmunosupresores/uso terapéutico , Masculino , Persona de Mediana Edad , Ventilación no Invasiva/métodos , Neumonía Viral/complicaciones , Neumonía Viral/epidemiología , Neumonía Viral/virología , SARS-CoV-2/inmunología , Receptores de Trasplantes , Resultado del Tratamiento , Equilibrio Hidroelectrolítico
5.
J Med Virol ; 92(10): 2019-2026, 2020 10.
Artículo en Inglés | MEDLINE | ID: covidwho-133656

RESUMEN

Coronavirus disease 2019 (COVID-19) had its evolution in Wuhan, Hubei Province, China, and now it has spread around the world, resulting in a large number of deaths. Temporary Ark hospitals (TAHs) have played an important role in controlling the spread of the epidemic in the city of Wuhan. Taking one TAH with 800 beds as an example, we summarized details of the layout, setting, working mode of medical staff, patient management, admission standards, discharge standards, and standards for transferring to another hospital, hospital operation, and so on. Over the period of operation, a total of 1124 patients were admitted for treatment. Of these, 833 patients were cured and discharged from the hospital and 291 patients were transferred to other designated hospitals, owing to aggravation of their condition. The achievement was to have zero infection for medical staff, zero in-hospital deaths among admitted patients, and zero readmission for discharged patients. The rapid deployment of TAH provided a suitable place for treating mild/moderate or no asymptomatic COVID-19 patients, which successfully helped to control the infection in Wuhan. The successful model of TAH would rapidly and effectively control the spread of COVID-19 in other cities.


Asunto(s)
COVID-19/terapia , Hospitales/clasificación , Pandemias , COVID-19/epidemiología , China/epidemiología , Mortalidad Hospitalaria , Hospitalización , Humanos , Control de Infecciones , Alta del Paciente/normas , Readmisión del Paciente
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA